CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen brokerages that are covering the firm, Marketbeat Ratings reports.

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As health secretary, RFK Jr. said he would divest interests in several companies—including CRISPR Therapeutics and Dragonfly Therapeutics—within 90 days, according to a Jan. 21 disclosure ...

Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.

CTX-320 is under clinical development by CRISPR Therapeutics and currently in Phase I for Atherosclerosis. According to GlobalData, Phase I drugs for Atherosclerosis have a 64% phase transition ...

After five months of intense competition on Sa Re Ga Ma Pa, Mumbai's Shradha Mishra emerged victorious, with Subhasree Debnath and Ujwal Motiram Gajbhar as runners-up. The finale featured ...

In 2022, the Framingham native was part of NBC’s Winter Olympics coverage and Apple TV’s “Friday Night Baseball” broadcasts. She’s a regular guest on the exceptional “Pablo Torre Finds ...